Inovio Pharmaceuticals (INO) Leases (2019 - 2025)
Inovio Pharmaceuticals (INO) has disclosed Leases for 7 consecutive years, with $6.5 million as the latest value for Q4 2025.
- Quarterly Leases fell 19.36% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2025, down 19.36% year-over-year, with the annual reading at $6.5 million for FY2025, 19.36% down from the prior year.
- Leases hit $6.5 million in Q4 2025 for Inovio Pharmaceuticals, down from $7.0 million in the prior quarter.
- In the past five years, Leases ranged from a high of $12.5 million in Q1 2021 to a low of $6.5 million in Q4 2025.
- Historically, Leases has averaged $9.6 million across 5 years, with a median of $9.5 million in 2023.
- Biggest five-year swings in Leases: decreased 6.86% in 2024 and later dropped 19.36% in 2025.
- Year by year, Leases stood at $11.6 million in 2021, then decreased by 11.61% to $10.2 million in 2022, then dropped by 7.2% to $9.5 million in 2023, then fell by 14.52% to $8.1 million in 2024, then fell by 19.36% to $6.5 million in 2025.
- Business Quant data shows Leases for INO at $6.5 million in Q4 2025, $7.0 million in Q3 2025, and $7.4 million in Q2 2025.